Linked Life Data

21112037

Source:http://linkedlifedata.com/resource/pubmed/id/21112037

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-11-29
pubmed:abstractText
Monitoring of the minimal residual disease (MRD) load has become essential for the choice of post-induction strategies in patients with acute myeloid leukemia (AML). Quantitative real-time and nested PCR guarantee highest sensitivities, but suitable markers for follow-up are available for ?60% of patients only: e.g. for those with reciprocal gene rearrangements or those with NPM1 mutations. On the other hand, for most AML patients, multiparameter flow cytometry (MFC) represents a good option for MRD monitoring. In virtually all AML patients, leukemia-associated immunophenotypes (LAIPs) are detectable with MFC. These can be targeted with high sensitivity ranging up to 10(-4) during the course of disease. Numerous studies demonstrated the prognostic power of the MRD levels determined by MFC at post-induction as well as post-consolidation time points in adults and children considered to be in hematologic remission of AML. The post-consolidation MRD status seems to have more prognostic power than post-induction levels. Thus, MFC can significantly contribute to risk assessment of patients with AML during and after treatment and allows clinicians to consider alternative strategies (e.g. allogeneic hematopoietic stem cell transplantation) earlier. Clinical studies need to focus on a standardization of these approaches to facilitate the translation of MFC-based MRD assessment into therapeutic decisions in patients with AML.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1532-1924
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
379-90
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
The role of multiparameter flow cytometry for disease monitoring in AML.
pubmed:affiliation
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377 Munich, Germany. wolfgang.kern@mll-online.com
pubmed:publicationType
Journal Article, Review